TriSalus Life Sciences, Inc. TLSI
3.48 USD -0.15 (-4.13%)
At closeNov 3, 2026, 4:01 PM EST
3.48 0.00 0.00%
After hours · Nov 3, 4:01 PM ET
3.40 Day range 3.77
2.20 52-week range 7.95
- YTD
- -50.14%
- 1 year
- -26.11%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 11.64 +234.6% upside
Now 3.48
- Target (low)
- 10.00
- Target (mean)
- 11.64
- Target (high)
- 16.00
Ratings (0m) 7 7 buy · 0 hold · 0 sell
- Strong buy2
- Buy5
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 7
- 1 month ago 6
- 2 months ago 5
- 3 months ago 4
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.35 | -0.35 – -0.35 | -1.56 | +77.6% | 8.04M | +40.5% | 1 |
| Next quarter | -0.31 | -0.31 – -0.31 | -0.60 | +48.3% | 9.26M | +43.3% | 1 |
| Current year | -1.27 | -1.27 – -1.27 | 0.00 | 0.0% | 29.21M | +57.8% | 1 |
| Next year | -1.00 | -1.00 – -1.00 | -1.27 | +21.3% | 44.88M | +53.7% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 17, 2024 | Cantor Fitzgerald | Initiated | — | Overweight |
| Nov 15, 2024 | Canaccord Genuity | Maintained | Buy | Buy |
| Nov 11, 2024 | Roth MKM | Initiated | — | Buy |
| Oct 25, 2024 | Northland Capital Markets | Initiated | — | Outperform |
| Sep 16, 2024 | Oppenheimer | Initiated | — | Outperform |
| Jun 27, 2024 | Canaccord Genuity | Maintained | Buy | Buy |
| May 30, 2024 | Canaccord Genuity | Initiated | — | Buy |
| May 10, 2024 | JonesTrading | Initiated | — | Buy |